RXST — RxSight, Inc.

RxSight Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Sales: $32.6 million, a 19% decline year-over-year, primarily due to lower LDD (Light Adjustable Lens) sales.
• LDD Units Sold: 25 units globally, generating $3 million in revenue, down from 83 units and $11 million in the prior year.
• LAL Sales: 28,611 units sold, down 2% year-over-year but up 10% sequentially, contributing $28.2 million, which accounted for 86% of total sales.
• Gross Margin: Improved to 77.5% from 71.6% year-over-year, driven by a higher mix of LAL sales.
• Net Loss: $9.2 million or $0.22 per share for Q4; adjusted net loss was $1.3 million or $0.03 per share.
• Full Year 2025 Sales: $134.5 million, a 4% increase year-over-year, with a significant decline in LDD revenue offset by a rise in LAL sales.
• Cash Position: Ended 2025 with approximately $228 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Installed Base Growth: LDD installed base increased by 17% to 1,134 units by year-end 2025.
• Clinical Validation: Positive results from a post-approval study were published, showing superior refractive accuracy of LAL technology.
• Market Positioning: RxSight is focusing on enhancing clinical outcomes and customer engagement, with a disciplined approach to capital placements.
• International Expansion: Building relationships with key opinion leaders in Europe, Asia, and Australia to support future growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $120 million and $135 million, implying a year-over-year decline of approximately 5% at the midpoint.
• Gross Margin Guidance: Projected to be 70% to 72%, reflecting anticipated pressures from inventory costs.
• Operating Expenses: Expected to range from $150 million to $160 million, reflecting ongoing investments in international expansion and U.S. sales efforts.
• Utilization Assumptions: Low single-digit growth for LALs anticipated, with Q1 expected to be the lowest quarter for sales.

4. Challenges and Points of Concern

• Declining LDD Sales: Significant drop in LDD sales and placements raises concerns about future revenue streams.
• Competitive Pressures: Anticipation of new premium IOL products from competitors could impact market share and pricing strategies.
• Market Conditions: The overall premium IOL market remains sensitive to macroeconomic factors, which could affect growth.

5. Notable Q&A Insights

• Market Health: Management expressed cautious optimism about a potential recovery in LAL sales, with a focus on improving utilization and practice engagement.
• Gross Margin Dynamics: The company is working through higher-cost inventory, which may impact margins in the near term but is expected to stabilize as inventory levels normalize.
• International Strategy: RxSight is taking a methodical approach to international expansion, focusing on building a foundation for long-term success in key markets.
• Competitive Environment: Management is monitoring competitive actions closely, acknowledging that while new product launches can create temporary headwinds, they typically revert to baseline over time.

This summary encapsulates the key points from RxSight's Q4 2025 earnings call, highlighting the company's financial performance, strategic direction, and outlook amidst ongoing challenges.